Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.

Inclusion Criteria

• •1. Written informed consent prior to screening procedures
• •2. Eastern Cooperative Oncology Grou (ECOG) Performance Status of 0, 1, or 2.
• •3. Patient with diagnosis of Ph+ CML-CP associated with BCR-ABL quantifiable by RQ-PCR (IS).
• •4. Patient has received a minimum of 3 months of imatinib or dasatinib treatment (any dose) since initial diagnosis with a documented response.
• •5. Patient is eligible for Pharmaceutical Benefits Scheme (PBS) reimbursed 1st line TKI treatment.
• •6. Patient has experienced non-hematological Adverse Events (AE(s)) of any grade, which persisted for at least 1 month despite supportive care or recurred at any grade at least once. Patients who, at the Investigator's discretion, require immediate discontinuation due to the severity of the adverse event are also eligible.
• •7. No other current or planned anti-leukemia therapies.
• •8. Adequate organ function.
• •9. Potassium, Magnesium and Total Calcium above Lower limit of normal.
• •10. life expectancy of more than 12 months in the absence of any intervention